Skip to main content
CP

Continuity Pharma

Continuity Pharma develops portable continuous flow manufacturing systems for the synthesis of essential generic medicines, enabling efficient production with a reduced manufacturing footprint. This technology directly addresses the issue of drug shortages, ensuring a reliable supply of critical medications for patients.

West Lafayette, United StatesFounded 20185200+ followers
Updated 20 months ago

Funding

$230K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

D
Funding rounds are not available yet.

Founders

Product

Problem

Drug shortages frequently disrupt patient care, placing a burden on the healthcare system and endangering patient safety due to lack of access to essential generic medicines. Traditional batch manufacturing processes can be inefficient, leading to supply chain vulnerabilities and hindering the timely production of critical medications.

Solution

Continuity Pharma develops and deploys portable, modular continuous flow manufacturing systems designed for the efficient synthesis of essential generic medicines. Their technology enables on-demand production with a reduced manufacturing footprint, addressing drug shortages and ensuring a reliable supply of critical medications. By optimizing the synthetic route for each application, Continuity Pharma's systems streamline the manufacturing process, improving efficiency and responsiveness to fluctuating demand. The company's approach aims to modernize pharmaceutical manufacturing, making it more agile and resilient in the face of supply chain challenges.

Target Audience

The primary target audience includes hospitals, healthcare systems, and government agencies seeking to ensure a stable supply of essential generic medicines and mitigate the impact of drug shortages.

Features

  • Portable, modular continuous flow manufacturing systems for on-site drug synthesis
  • Optimized synthetic routes for efficient processing of materials
  • Reduced manufacturing footprint compared to traditional batch processes
  • Rapid deployment and scalability to address immediate drug shortage needs
This profile is AI-generated and may contain inaccuracies.